RE:RE:RE:Observation of mineMy opinio, for what it's worth, is that it has to do with the market cap and number of shares. If you look at other biotech companies the number of oustanding shares are close to 100M not 600M. At this stage of the game, with no serious revenues, how can the market cap be higher that what it is.